Physician profile
Wilbur Jackson Strader
NPI 1740283043
$10,514.65
in general payments reported to CMS, 2019-2025
29 companies · $24.24 in 2025
The $24.24 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,115 · 2020: $1,380 · 2021: $3,035 · 2022: $747 · 2023: $758 · 2024: $455 · 2025: $24.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,613.91 | 2019-2024 | Synthroid |
| Novo Nordisk INC | $1,964.74 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,091.83 | 2019-2024 | Evenity, Prolia |
| Lilly USA, LLC | $494.31 | 2019-2024 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $490.87 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $420.02 | 2019-2021 | |
| Horizon Therapeutics Plc | $322.01 | 2021-2023 | Tepezza |
| Radius Health, INC. | $308.19 | 2019-2023 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.42 | 2019-2023 | Jardiance |
| Abbott Laboratories | $215.17 | 2019-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $205.85 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $167.37 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $167.30 | 2019-2022 | |
| Beta Bionics, INC. | $164.67 | 2024 | Ilet Bionic Pancreas |
| Inspire Medical Systems, INC. | $109.25 | 2023 | Inspire |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $104.10 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $68.00 | 2021-2023 | Signifor Lar, Isturisa |
| Corcept Therapeutics | $51.40 | 2020-2023 | Korlym |
| Arbor Pharmaceuticals, INC. | $36.28 | 2021 | |
| Dexcom, INC. | $35.33 | 2021 | |
| Esperion Therapeutics, INC. | $30.63 | 2021 | |
| Shire North American Group INC | $28.25 | 2019 | |
| Insulet Corporation | $23.60 | 2023 | Omnipod |
| Ibsa Pharma INC. | $22.05 | 2020 | |
| Mannkind Corporation | $18.63 | 2022 | |
| Medtronic Minimed, INC. | $15.13 | 2020 | |
| Antares Pharma, INC. | $14.75 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.14 | 2021 | |
| Medtronic, INC. | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilbur Strader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.